Enovis (NYSE:ENOV) Upgraded by Wall Street Zen to Buy Rating

Wall Street Zen upgraded shares of Enovis (NYSE:ENOV) from a hold rating to a buy rating in a report released on Monday.

Several other brokerages also recently weighed in on ENOV. William Blair initiated coverage on shares of Enovis in a research note on Friday, April 17th. They issued an “outperform” rating for the company. Zacks Research lowered Enovis from a “hold” rating to a “strong sell” rating in a report on Tuesday, June 30th. Wells Fargo & Company lowered their price objective on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th. Finally, Evercore reaffirmed an “outperform” rating and set a $36.00 target price on shares of Enovis in a research report on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $43.83.

Enovis Stock Performance

Shares of Enovis stock opened at $26.15 on Monday. The company has a market capitalization of $1.51 billion, a PE ratio of -1.32 and a beta of 1.39. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The company has a 50-day simple moving average of $23.29 and a two-hundred day simple moving average of $23.84. Enovis has a one year low of $19.14 and a one year high of $36.82.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The business had revenue of $589.15 million for the quarter, compared to analysts’ expectations of $572.02 million. During the same period last year, the business earned $0.81 EPS. The company’s revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Research analysts expect that Enovis will post 3.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Oliver Engert acquired 1,200 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were acquired at an average cost of $21.62 per share, with a total value of $25,944.00. Following the completion of the acquisition, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. In the last quarter, insiders bought 4,200 shares of company stock worth $92,084. 2.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Enovis

A number of large investors have recently bought and sold shares of the company. Arax Advisory Partners acquired a new position in Enovis in the 4th quarter worth approximately $29,000. EverSource Wealth Advisors LLC lifted its stake in Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares during the period. GAMMA Investing LLC lifted its stake in Enovis by 353.5% during the 4th quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after acquiring an additional 1,446 shares during the period. Danske Bank A S purchased a new stake in shares of Enovis in the 3rd quarter valued at $64,000. Finally, iSAM Funds UK Ltd purchased a new stake in shares of Enovis in the 3rd quarter valued at $80,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.